Title : The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.

Pub. Date : 2012 Feb

PMID : 23148190






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 After 6 and 12 months the GH levels decreased to 1.61 +- 0.86 ng/ml (range: 0.7-2.65) and 1.85 +- 2.40 ng/ml (range: 0.0-8.3), respectively, while the IGF-1 became 305.90 +- 43.19 ng/ml after 6 months of treatment (range: 240-376) and 256.99 +- 71.43 ng/ml after 12 months of octreotide treatment (range: 126-325), respectively. Octreotide growth hormone 1 Homo sapiens
2 CONCLUSIONS: Octreotide treatment of acromegaly not only decreases GH and IGF-1 concentrations, but also appears to diminish the size of the tumor in about 60% of cases. Octreotide growth hormone 1 Homo sapiens